Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.64 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3037290 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4HPGDMAPTLMNA | |
| SCHEMBL5149377 | 0.95 | CHRNB2 (0.62) | CHRNB2CHRNA4HPGDMAPTLMNA | |
| SCHEMBL4343371 | 0.94 | CHRNB2 (0.61) | CHRNB2CHRNA4HPGDMAPTLMNA | |
| SCHEMBL7873589 | 0.92 | CHRNB2 (0.66) | CHRNB2CHRNA4HPGDLMNALTA4H | |
| Hydrochloric Acid SCHEMBL5405414 | 0.90 | CHRNB2 (0.64) | CHRNB2CHRNA4HPGDLMNALTA4H | |
| SCHEMBL14028449 | 0.88 | CHRNB2 (0.69) | CHRNB2CHRNA4HPGDMAPTLMNA | |
| SCHEMBL15498199 | 0.88 | CHRNB2 (0.73) | CHRNB2CHRNA4HPGDMAPTLMNA | |
| SCHEMBL11307294 | 0.87 | CHRNB2 (0.64) | CHRNB2CHRNA4HPGDMAPTLMNA | |
| SCHEMBL16943480 | 0.85 | CHRNB2 (0.66) | CHRNB2CHRNA4HPGDMAPTLMNA | |
| SCHEMBL3975841 | 0.85 | CHRNB2 (0.66) | CHRNB2CHRNA4HPGDMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2518063-B1 | Pyridazinones and furan-containing compounds | SLOAN-KETTERING INST FOR CANCER RES (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2099770-B1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN KETTERING INST CANCER (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2518063-A1 | Pyridazinones and furan-containing compounds | Sloan-Kettering Institute For Cancer Research (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2008080056-A2 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-07-03 | — | — | WO | disclosed |
| US-5663194-A | SCHIZOPHRENIA | WYETH | 1997-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | CHRNB2 3411/4885CHRNA4 4210/4885HPGD 115/4885 |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | CHRNB2 3411/4885CHRNA4 4210/4885HPGD 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.